PacBio Reports Director Changes and Executive Appointments

TL;DR

PacBio's board is shaking up: new directors elected, execs appointed, and compensation plans updated.

AI Summary

Pacific Biosciences of California, Inc. (PacBio) filed an 8-K on June 6, 2025, reporting on several key events that occurred on June 4, 2025. These include the departure of a director, the election of new directors, the appointment of certain officers, and the adoption of new compensatory arrangements. The filing also covers the submission of matters to a vote of security holders and includes financial statements and exhibits.

Why It Matters

Changes in board composition and executive appointments can signal shifts in company strategy or governance, potentially impacting future performance and investor confidence.

Risk Assessment

Risk Level: medium — Changes in leadership and governance can introduce uncertainty, but the filing also indicates routine corporate actions like shareholder votes and financial reporting.

Key Numbers

• 001-34899 — Commission File Number (Identifies the SEC filing for the company.)
• 16-1590339 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Pacific Biosciences of California, Inc. (company) — Registrant
• June 4, 2025 (date) — Date of earliest event reported
• June 6, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of incorporation
• 1305 O'Brien Drive (address) — Principal executive office address
• Menlo Park, California 94025 (address) — Principal executive office location

FAQ

From the Filing

0001299130-25-000140.txt : 20250606 0001299130-25-000140.hdr.sgml : 20250606 20250606162108 ACCESSION NUMBER: 0001299130-25-000140 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250604 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250606 DATE AS OF CHANGE: 20250606 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 251030991 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 8-K 1 pacb-20250604.htm 8-K pacb-20250604 0001299130 false 0001299130 2025-06-04 2025-06-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 4, 2025 Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34899 16-1590339 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1305 O’Brien Drive Menlo Park , California 94025 (Address of principal executive offices) (Zip Code) ( 650 ) 521-8000 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o ITEM 5.02.    DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On April 22, 2025, the board of directors (the "Board") of Pacific Biosciences of California, Inc. (the “Company”), at the recommendation of the compensation committee of the Board, approved an amendment (the “Amendment”) to the Company’s 2020 Equity Incentive Plan (the “2020 Plan&#